We show that activators of the reductive stress response E3 CUL2FEM1B boost degradation of multiple physiological substrates to improve mitochondrial import and electron transport chain assembly. In this manner, CUL2FEM1B agonists preserve mitochondrial function and neuronal survival in models of neurodegenerative COX deficiency syndrome and Friedreich’s ataxia.
Researchers have now developed a strategy called stimulated protein degradation (SPD), which activates the cell's natural protein-clearance system to accelerate the breakdown of multiple proteins.The compound also demonstrated beneficial effects in cellular models of other mitochondrial disorders, including Friedreich's ataxia, an inherited condition associated with a deficiency of the protein frataxin.
In the experimental model, BD2 produced effects comparable to those observed with optimal concentrations of omaveloxolone, an approved treatment for Friedreich's ataxia. However, the approach did not correct every mitochondrial defect tested.
